Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Review, H2 2016', provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted pipeline therapeutics. 

The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) 
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Overview 7
Therapeutics Development 8
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Products under Development by Stage of Development 8
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Products under Development by Therapy Area 9
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Products under Development by Indication 10
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Products under Development by Companies 13
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Companies Involved in Therapeutics Development 21
Acceleron Pharma, Inc. 21
Amgen Inc. 22
Bristol-Myers Squibb Company 23
Milo Biotechnology LLC 24
Pfizer Inc. 25
Regeneron Pharmaceuticals Inc 26
Sarepta Therapeutics, Inc. 27
Scholar Rock, Inc. 28
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Drug Profiles 29
AAV1-Follistatin - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AAV9-Follistatin - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ACE-083 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ACE-2494 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ACE-2798 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ATA-842 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
BMS-986089 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
domagrozumab - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
luspatercept - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
OSX-200 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
SRK-015 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
trevogrumab - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Dormant Projects 51
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Discontinued Products 52
Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Featured News & Press Releases 53
Oct 13, 2016: Acceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher and Provide Overview of ACE-083 Phase 2 Trial 53
Oct 02, 2016: Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis 53
Jul 08, 2016: Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases 53
Jun 29, 2016: Acceleron Announces Presentation of ACE-083 Phase 1 Healthy Volunteer Data at the 14th International Congress on Neuromuscular Disease 54
Jun 10, 2016: Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association 55
Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association 56
May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association 57
May 09, 2016: Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients 58
Dec 07, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes 58
Dec 05, 2015: Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition 59
Dec 01, 2015: Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting 60
Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting 61
Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event 61
Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-083 at the 20th International Annual Congress of the World Muscle Society 62
Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-2494 at the 20th International Annual Congress of the World Muscle Society 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Acceleron Pharma, Inc., H2 2016 21
Pipeline by Amgen Inc., H2 2016 22
Pipeline by Bristol-Myers Squibb Company, H2 2016 23
Pipeline by Milo Biotechnology LLC, H2 2016 24
Pipeline by Pfizer Inc., H2 2016 25
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 26
Pipeline by Sarepta Therapeutics, Inc., H2 2016 27
Pipeline by Scholar Rock, Inc., H2 2016 28
Dormant Projects, H2 2016 51
Discontinued Products, H2 2016 52